Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PANC561

Financiado

Cerrado

LAM561 BEATS PANCREATIC CANCER

Pancreatic cancer is a highly aggressive type of cancer, with poor prognosis and few effective therapeutic options. At the time of diagnosis only 20% of patients are eligible for surgery, the development of metastasis has already... ver más

31/03/2023

LAMINAR PHARMACEUT...

161K€

Presupuesto del proyecto: 161K€

Líder del proyecto

LAMINAR PHARMACEUTICALS La investigacion sobre temas de salud humana. el diseño e investigacion defarmacos y productos dieteticos para terapia humana y veterinaria...

TRL 3-4 | 130K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-03-31

MSCA-IF-2020: Individual Fellowships

I+D

Cerrada hace 4 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

LAMINAR PHARMACEUTICALS

160.93K€ | Lider

Proyectos interesantes

CPP2021-009064

Medical Technol...

Pharmaceutical...

1K€ Cerrado

PanC-ASAP

Medical Technol...

Pharmaceuticals

3M€ Cerrado

FIBROHALT

Medical Technol...

Biotechnology

71K€ Cerrado

MEMBRANELIPIDTHERAPY

Medical Technol...

Pharmaceuticals

173K€ Cerrado

PDC2022-133188-I00

Medical Technol...

Pharmaceutical...

150K€ Cerrado

INC-TU-2012-2617

Medical Technol...

Pharmaceutical...

160K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 24 meses Fecha Inicio: 2021-03-09
Fecha Fin: 2023-03-31

Líder del proyecto

LAMINAR PHARMACEUTICALS La investigacion sobre temas de salud humana. el diseño e investigacion defarmacos y productos dieteticos para terapia humana y veterinaria...

TRL 3-4 | 130K€

Presupuesto del proyecto 161K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Pancreatic cancer is a highly aggressive type of cancer, with poor prognosis and few effective therapeutic options. At the time of diagnosis only 20% of patients are eligible for surgery, the development of metastasis has already occurred. The life expectancy of these patients is 6-11 months (stage3) or 2-6 months (stage IV). Laminar Pharmaceuticals SL is pioneer in the development of bioactive molecules that act through modulation of the lipid composition of the cell membrane regulating key signaling pathways for different pathologies, including cancer. Recently, Laminar Pharma has demonstrated the high safety and promising efficacy of its most advanced drug in clinical development, LAM561 which is being developed for the treatment of glioblastoma. The clinical study phase IIb/III of LAMP561 in glioblastoma, which evaluates the pharmacological safety of LP561 in combination with the standard treatment for this disease, is currently being completed, without observed severe adverse effects attributable to LAM561. The current project aims to carry out a preclinical study to evaluate the efficacy and safety of the anti-tumor drug LAM561 in cell and animal models of pancreatic cancer as monotherapy or in combination with standard chemotherapeutics. In addition, the study of cell migration in cell and animal models of pancreatic cancer may allow to explore the antimetastatic effect of LP561 pancreatic cancer, opening a new line of development in the company. This project aims to expand the product indications by including data on its safety and efficacy in the treatment of pancreatic cancer which requires urgent solutions. Therefore, the completion of the preclinical study would allow, at the end of the proposed studies, to launch human clinical trials to give pancreatic cancer patients the option of benefiting from this therapy more quickly. Furthermore, this represents a great opportunity which may foster the carrier of the current applicant researcher.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores